Hollywood, July 27, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCPINK: ETST), an innovative biotech company focused on industrial hemp, cannabinoid research and development, nutraceuticals, pharmaceuticals, finalizes new KannaBidioiD e-liquid labels and updates shareholders.

ETST’s new wholly owned subsidiary, KannaBidioiD, Inc. announced in June, and its joint venture announced in early July, has finalized its first four product labels. KannaBidioiD will launch its website within two weeks, and the first line of products will be available by the end of August.

David Plante, KannaBidioiD’s President commented, “I’m very pleased with our new labels and feel that they are going to truly stand out on store shelves as well as all the positive feedback on our sample batch from store owners and distributors. We look to have our first batch of 4,000 units sold based on preorders and rising demand. I truly look forward to launching this amazing line and sharing the great success and foresee this KBD product to be an absolute game changer.”

ETST is also working on an extensive agreement with a communications agency to brand and market its new MSN-2 medical device, and CBD-based products. The communications agency will help create an attractive name and a new transactional website, to sell the medical devices and associated laboratory tests. With the help of the company’s new advisory board member, Dr. Michel Gauthier M.D., ETST plans to have all the partners ready to launch the medical device during Q1 2018, and help develop ETST’s CBD based pharmaceutical generic drug study. ETST looks to start a pre-clinical study partnership with a Canadian university, to develop a breast cancer treatment, as well as a separate partnership with a group of physicians to conduct clinical studies, to help individuals with epileptic and non-epileptic seizures by Q4 2017.

Dr. Michel Aube, ETST’s CEO & CSO states, “I’m happy to see our progress and all the amazing partnerships we have formed. We have had some delay in the SOP writing due to us wanting to partner with an accredited research center to qualify and receive grants for all our R&D activities in Canada, and we look to be finalizing a strong partnership very soon. I look forward on sharing many exciting achievements my team has succeeded in and the research center partnership once finalized.”

Nickolas S. Tabraue, ETST’s President, Director, and COO comments, “I’m pleased to see our new wholly owned Subsidiary KannaBidioiD progressing and all David Plante’s work. We are also in the cusps on finalizing many international distribution channels and partnerships that will catapult our revenue stream with our current CBD product line. The company’s management team has been working very hard, and management looks forward to sharing many exciting updates very soon. Earth Science Tech greatly appreciates all its loyal shareholders who have been invested in the company since the beginning.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. T
To learn more please visit: www.Earthsciencetech.com

View ETST's accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit: www.Earthsciencepharmaceutical.com

The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit: www.Cannabisthera.com 

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties. 
Website coming soon: www.Kannabidioidinc.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations  
Dave Demarest 

Earth Science Tech, Inc.  
Nickolas S. Tabraue, P/D/COO